GBO's offer for Vigmed: Supplement to the offer document made public

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, New Zealand, South Africa or the United States or in any other jurisdictions where such offer pursuant to legislation and regulations in such relevant jurisdictions would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important notice” at the end of this announcement and in the tender offer document which has been published on GBO's website for the Offer, www.gbo-vigmed.se/en/.

On 27 February 2017, Greiner Bio-One GmbH ("GBO") announced a recommended public offer to the shareholders of Vigmed Holding AB (publ) ("Vigmed") to tender all shares in Vigmed to GBO (the "Offer") for a consideration of SEK 1.00 in cash per share, which has been increased to SEK 1.20 in cash per share (see below). The offer document regarding the Offer was made public on 5 March 2017.

On account of the statement from the independent bid committee of Vigmed on 10 April 2017 and the press release from GBO that was released on 13 April 2017 regarding the increase of the consideration in the Offer, GBO has prepared a supplement to the offer document which includes the mentioned documents. The supplement has been made public today and is, together with the offer document, and the acceptance form, available on GBO's website for the Offer (www.gbo-vigmed.se/en/) and on SEB’s website for prospectuses (www.sebgroup.com/prospectuses). The supplement should be read in conjunction with the offer document of 5 March 2017. For the other terms and conditions of the Offer please refer to the offer document.

Greiner Bio-One GmbH

For additional information, please contact:

Georg Heftberger, Chief Financial Officer, Greiner Bio-One GmbH, tel. +43 664 8841 0683

Eric Tapper, Hallvarsson & Halvarsson, tel. +46 8 407 21 80

For information and documentation regarding the Offer, please visit: www.gbo-vigmed.se/en/

This press release was submitted for publication on 20 April 2017 at 8:00 a.m. CEST.